Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.
Separately, HC Wainwright raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 10th.
Read Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Industrial Products Stocks Investing
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
